Over-the-Counter Medications: FDA Rules, Labels, and Recalls

The FDA rules for over-the-counter medications set who can sell a nonprescription drug, what has to appear on the package, which products can only be bought with ID or age verification, and what a manufacturer must do when someone is seriously harmed. Two approval pathways feed the shelf: a published monograph that pre-clears well-known ingredients, and an individual new drug application for anything outside those monographs. Everything else — labeling, packaging, advertising, adverse-event reporting, recalls, penalties — layers on top of that basic approval question.

How an OTC Drug Is Allowed on the Shelf

Most OTC drugs reach the market through the monograph system. Under 21 CFR Part 330, the FDA publishes monographs listing active ingredients recognized as safe and effective for self-treatment, along with acceptable doses, formulations, and labeling.¹ A manufacturer that follows every condition in the relevant monograph can sell the product without going through individual FDA approval. That is why many brands can sell the same acetaminophen, ibuprofen, or diphenhydramine product without each one being approved separately.

When a product does not fit an existing monograph, the manufacturer has to file a New Drug Application and submit clinical data proving the product is safe and effective for its intended OTC use. The FDA evaluates that data under 21 CFR Part 314 before granting approval.² It is slower and more expensive, and it is the only path for novel formulations or ingredients the monograph system has not addressed.

The CARES Act of 2020 added Section 505G to the Federal Food, Drug, and Cosmetic Act, letting the FDA update monographs through administrative orders instead of full rulemaking.³ Ingredient approvals, safety information, and labeling requirements can now be revised without the multi-year delays the old process caused.

What the Label Must Show

Every OTC medication sold in the United States has to carry a standardized Drug Facts panel. The format is set by 21 CFR 201.66 and is deliberately rigid: fixed order, minimum font sizes, and a layout designed to prevent misreading.⁴ The panel runs in this order: active ingredients with the amount per dose; purpose (the therapeutic category, such as “pain reliever”); uses (the specific symptoms treated); warnings (when to avoid the product, when to call a doctor, side effects, and interactions); directions, including the maximum amount allowed within 24 hours; other information, such as storage; and finally the full list of inactive ingredients, which is where allergens like certain dyes and preservatives show up.

The warnings section is the part worth reading before you try a new product. Drug interaction risks, age restrictions, and conditions that make the product unsafe all live there.

Tamper-Evident Packaging

Under 21 CFR 211.132, OTC drug products must use tamper-evident packaging — indicators or barriers that show visible evidence if the product has been opened before purchase.⁵ The packaging has to be distinctive enough that it cannot be easily replicated with everyday materials, and two-piece hard gelatin capsules must be sealed with an approved technology. The label itself has to describe the tamper-evident feature so you can tell what an intact package should look like.

Expiration Dates

Most OTC drugs carry an expiration date based on stability testing that confirms the product meets its labeled strength and quality through that date, under the storage conditions on the label. That requirement sits in 21 CFR 211.137.⁶ Products that must be mixed before use need expiration information for both the unmixed and mixed forms. Homeopathic products are exempt, and OTC drugs with no dosage limitations that remain stable for at least three years, supported by testing data, are not currently required to display an expiration date.

Products You Cannot Just Pick Off the Shelf

Some OTC products are legal without a prescription but still carry purchase restrictions because their ingredients can be diverted for illegal use.

Pseudoephedrine, Ephedrine, and Phenylpropanolamine

The Combat Methamphetamine Epidemic Act of 2005 put federal controls on products containing pseudoephedrine, ephedrine, and phenylpropanolamine.⁷ These products have to sit behind the pharmacy counter or in locked cabinets. To buy one, you present a government-issued photo ID and sign a logbook (electronic or paper) recording your name, address, the product, the quantity, and the date and time of sale.⁸

Federal law caps purchases at 3.6 grams of base ingredient per day and 9 grams within any 30-day period. Of that 30-day total, no more than 7.5 grams can arrive through mail order or delivery. Knowingly exceeding these limits is a federal offense. Falsifying the logbook triggers penalties under 18 U.S.C. § 1001, which carries fines up to $250,000 and up to five years in prison.⁷ Retailers must keep logbook records for at least two years, verify the purchaser’s name against the ID, and certify that every employee who handles these sales has been trained. One narrow exception: a single-package sale containing no more than 60 milligrams of pseudoephedrine is exempt from the logbook requirement.⁸

Dextromethorphan Age Limits

Cough suppressants containing dextromethorphan face age-based purchase restrictions in a growing number of states, though no federal law currently sets a minimum age. More than 20 states prohibit sales to anyone under 18 and require retailers to check ID. Specific rules vary — some states require ID only when the buyer appears under 25 — but the baseline is the same: 18 to buy, with penalties on the retailer for selling to a minor.

Advertising Claims and Who Enforces Them

Regulation of OTC drug marketing is split. The FDA controls labeling, meaning everything on or attached to the product, including the Drug Facts panel, package inserts, and claims printed on the box. The Federal Trade Commission controls advertising: television, online, print, and any promotional material that is not physically on the product.⁹ Prescription drug advertising is the one exception; the FDA handles that directly.

The FTC applies what it calls a “competent and reliable scientific evidence” standard. In practice, health-related advertising claims generally need to be backed by randomized, controlled human clinical trials, not by lab studies or testimonials alone.¹⁰ The research must be conducted and evaluated by qualified experts and be sufficient in quality and quantity by accepted standards in the relevant field. Manufacturers that overstate what a product can do, or that cherry-pick data, face FTC enforcement.

Reporting a Serious Reaction

Under 21 U.S.C. § 379aa, a “serious adverse event” from an OTC drug includes death, a life-threatening experience, hospitalization, a persistent disability, a birth defect, or a condition requiring medical intervention to prevent one of those outcomes.¹¹

Manufacturers (the statute calls them “responsible persons”) must submit a report to the FDA within 15 business days of receiving a report of a serious adverse event.¹¹ Reports are filed on FDA Form 3500A and must include patient information, a description of the event and its outcome, product details, and information about who initially reported the problem. Every OTC drug label must include a domestic address or phone number for adverse-event reports to the manufacturer, and it is that contact that starts the 15-day clock.

You can also report a problem directly to the FDA through the MedWatch program, which accepts voluntary safety reports for both prescription and OTC drugs.¹² You do not have to go through the manufacturer first.

Recalls and Penalties When a Product Breaks the Rules

Most drug recalls are voluntary. The manufacturer identifies a problem — contamination, mislabeling, wrong dosage — and pulls the product. The FDA classifies recalls by risk:¹³

Class I: reasonable probability of serious health consequences or death.
Class II: may cause temporary or reversible health problems, or where the chance of serious consequences is remote.
Class III: not likely to cause any adverse health consequences.

The FDA can only order a mandatory recall for controlled substances, and only when the manufacturer refuses to act voluntarily and there is a reasonable probability of serious harm or death.¹⁴ For most OTC drugs, the agency relies on voluntary cooperation, backed by the possibility of seizure or an injunction.

Selling an adulterated or misbranded drug violates 21 U.S.C. § 331. A first-time violation is a misdemeanor carrying up to one year in prison, a fine of up to $1,000, or both. A prior conviction, or acting with intent to defraud, raises the penalties to up to three years in prison and fines up to $10,000. Knowingly adulterating a drug in a way that creates a reasonable probability of serious harm or death is a felony punishable by up to 20 years in prison and fines up to $1,000,000.¹⁵ The FDA can also seize noncompliant products and seek court injunctions without a criminal conviction.

OTC Drugs Are Not Dietary Supplements

OTC drugs and dietary supplements often sit on adjacent shelves, and the legal frameworks are not the same. OTC drugs must be shown to be safe and effective before they are sold, through either the monograph system or an NDA. Dietary supplements face no pre-market approval; the manufacturer is responsible for safety, and the FDA can act only after a problem surfaces.

Dietary supplements also cannot legally claim to treat, cure, or prevent any disease. Their labels are limited to “structure/function” claims such as “supports immune health,” not therapeutic claims like “reduces fever.” A product that claims to treat a specific medical condition but is labeled as a supplement is a warning sign: either the claim is illegal, or the product has not gone through the review OTC drugs require. The quickest check is the panel on the back. A Drug Facts panel means it is an OTC drug; a Supplement Facts panel means it is a supplement operating under a lighter framework.

1
eCFR. 21 CFR Part 330 – Over-the-Counter (OTC) Human Drugs Which Are Generally Recognized as Safe and Effective and Not Misbranded
2
eCFR. 21 CFR Part 314 – Applications for FDA Approval to Market a New Drug
3
U.S. Food and Drug Administration. Over-the-Counter (OTC) Drug Review – OTC Monograph Reform in the CARES Act
4
eCFR. 21 CFR 201.66 – Format and Content Requirements for Over-the-Counter (OTC) Drug Product Labeling
5
eCFR. Tamper-Evident Packaging Requirements for Over-the-Counter (OTC) Human Drug Products
6
eCFR. Expiration Dating
7
Drug Enforcement Administration. CMEA General Information
8
Federal Register (govinfo.gov). Retail Sales of Scheduled Listed Chemical Products
9
Federal Trade Commission. Memorandum of Understanding Between the Federal Trade Commission and the Food and Drug Administration
10
Federal Trade Commission. Health Products Compliance Guidance
11
Office of the Law Revision Counsel. 21 U.S. Code 379aa – Serious Adverse Event Reporting for Nonprescription Drugs
12
U.S. Food and Drug Administration. MedWatch – FDA Safety Information and Adverse Event Reporting Program
13
U.S. Food and Drug Administration. Recalls Background and Definitions
14
U.S. Food and Drug Administration. Understanding Drug Recalls with Dr. Ileana Elder
15
Office of the Law Revision Counsel. 21 U.S.C. 333 – Penalties